Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults

Lemborexant, a dual orexin receptor antagonist, is approved for the treatment of insomnia and is under investigation for treating other sleep disorders. Here we summarize pharmacokinetic, pharmacodynamic, and safety data from 3 randomized, double‐blind, placebo‐controlled phase 1 studies: single asc...

Descripción completa

Detalles Bibliográficos
Autores principales: Landry, Ishani, Nakai, Kenya, Ferry, Jim, Aluri, Jagadeesh, Hall, Nancy, Lalovic, Bojan, Moline, Margaret L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891412/
https://www.ncbi.nlm.nih.gov/pubmed/32468649
http://dx.doi.org/10.1002/cpdd.817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891412/
https://www.ncbi.nlm.nih.gov/pubmed/32468649
http://dx.doi.org/10.1002/cpdd.817

Ejemplares similares